A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder

Psychopharmacology

Volumn 228, Issue 2, 2013, Pages 175-185

  Takeuchi, Hiroyoshi ^a,b   Remington, Gary ^a  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antipsychotics; Aripiprazole; Psychotic symptoms; Schizophrenia; Worsening

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BIPERIDEN; BISOPROLOL; CARBAMAZEPINE; CLONAZEPAM; FLUVOXAMINE; HALOPERIDOL; LITHIUM; LORAZEPAM; MEPHENOXALONE; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIFLUOPERAZINE; VALPROIC ACID; VENLAFAXINE;

ADULT; AGED; AGGRESSION; AGITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DELUSION; DISEASE DURATION; DISORIENTATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; EPIDEMIC; FEMALE; HALLUCINATION; HUMAN; MALE; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84879963702     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3154-1     Document Type: Review

References (39)

1. Adan-Manes J, Garcia-Parajua P (2009) Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. J Clin Pharm Ther 34:245-246
2. Ahuja N, Lloyd AJ (2007) Aripiprazole and worsening of psychosis: a case report. J Clin Psychiatry 68:805-806
3. Aubry JM, Simon AE, Bertschy G (2000) Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases. J Clin Psychiatry 61:649-655
4. Avari J, Mahgoub N, Alexopoulos GS (2011) Adding aripiprazole to clozapine worsened delusions and hallucinations: a case report. J Clin Psychopharmacol 31:528-531
5. Barnas ME, Hussain N, Petrides G (2005) Treatment-emergent psychosis with aripiprazole. J Clin Psychiatry 66:1339
6. Benyamina A, Samalin L (2012) Atypical antipsychotic-induced mania/hypomania: a review of recent case reports and clinical studies. Int J Psychiatry Clin Pract 16:2-7
7. Burke MJ, Lincoln J (2006) Aripiprazole and haloperidol: a clinically relevant interaction with a dopamine antagonist and partial agonist. Ann Clin Psychiatry 18:129-130
8. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302:381-389
9. Chiu YH, Chen CH, Lu ML (2011) Worsening psychosis after adding aripiprazole to clozapine. Prog Neuropsychopharmacol Biol Psychiatry 35:291-292
10. Cho DY, Lindenmayer JP (2009) Aripiprazole-induced agitation after clozapine discontinuation: a case report. J Clin Psychiatry 70:141-143
11. DeLeon A, Patel NC, Crismon ML (2004) Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666
12. DeQuardo JR (2004) Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism? J Clin Psychiatry 65:132-133
13. Ducroix C, Beghelli F, Rousset I, Vacheron MN (2008) Emergent mania with atypical antipsychotics: review of the literature about one case. Therapie 63:153-154
14. Fleischhacker WW, Heikkinen ME, Olie JP, Landsberg W, Dewaele P, McQuade RD, Loze JY, Hennicken D, Kerselaers W (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13:1115-1125
15. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167:686-693
16. Glick ID, Duggal V, Hodulik C (2006) Aripiprazole as a dopamine partial agonist: positive and negative effects. J Clin Psychopharmacol 26:101-103
17. Grover S, Sharan P, Gupta N (2006) Aripiprazole worsens psychosis: a case report. Prim Care Companion J Clin Psychiatry 8:380-381
18. Jaskiw GE, Popli AP (2004) A meta-analysis of the response to chronic l-dopa in patients with schizophrenia: therapeutic and heuristic implications. Psychopharmacology (Berl) 171:365-374
19. Kapusta ND, Mossaheb N, Barnas C, Fischer P (2007) Aripiprazole-induced psychosis: a case report of reexposure by stepwise up-titration. J Clin Psychiatry 68:1445-1446
20. Lea JW, Stoner SC, Lafollette J (2007) Agitation associated with aripiprazole initiation. Pharmacotherapy 27:1339-1342
21. Letmaier M, Painold A, Holl AK, Grohmann R, Vergin H (2012) Severe psychotic exacerbation during combined treatment with aripiprazole/haloperidol after prior treatment with risperidone. Int J Psychiatry Clin Pract 16:153-156
22. Lieberman JA, Kane JM, Alvir J (1987) Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 91:415-433
23. Lin HC, Chong MY, Lee Y, Yeh WC, Lin PY (2009) Switching of antipsychotics to aripiprazole in the treatment of schizophrenia. Chang Gung Med J 32:409-416
24. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, Saha A, Ali M, Iwamoto T (2003) Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61:123-136
25. Michalopoulou PG, Lykouras L (2006) Manic/hypomanic symptoms induced by atypical antipsychotics: a review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry 30:549-564
26. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535
27. Moncrieff J (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand 114:3-13
28. Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'Italien GJ, Nys M, Carson WH, McQuade RD (2008) A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 69:1046-1056
29. Padala PR, Wengel SP, Petty F (2007) Manic episode during treatment with aripiprazole. Am J Psychiatry 164:172-173
30. Ponde MP, Novaes CM (2007) Aripiprazole worsening positive symptoms and memantine reducing negative symptoms in a patient with paranoid schizophrenia. Rev Bras Psiquiatr 29:92
31. Rachid F, Bertschy G, Bondolfi G, Aubry JM (2004) Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry 65:1537-1545
32. Raja M (2007) Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. Int J Neuropsychopharmacol 10:107-110
33. Ramaswamy S, Vijay D, William M, Sattar SP, Praveen F, Petty F (2004) Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 19:45-48
34. Reeves RR, Mack JE (2004) Worsening schizoaffective disorder with aripiprazole. Am J Psychiatry 161:1308
35. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, Shon JH, Conley RR (2007) Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 164:1404-1410
36. Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, Kapur S, Zipursky RB, Wilson AA, Christensen BK, Seeman P (2000) Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 152:174-180
37. Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA (2011) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168:947-956
38. Takeuchi H, Uchida H, Suzuki T, Watanabe K, Kashima H (2009) Predictors of clinical worsening after a switch to aripiprazole in patients with schizophrenia: a 1-year naturalistic follow-up study. J Clin Psychopharmacol 29:394-395
39. Traber R, Schneiter R, Modestin J (2007) A case of aripiprazole-induced mania. Pharmacopsychiatry 40:37-38